[November 25, 2015]

Research and Markets: Sustained Release Ocular Drug Delivery Systems Market to Reach USD 6.5 Billion by 2025 - Market Analysis and Forecast 2015 - 2025 (2nd edition)

Research and Markets (http://www.researchandmarkets.com/research/sz483m/sustained_release) has announced the addition of the "Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition)" report to their offering.

The 2nd edition of the Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 report features an in-depth review of the emerging market for implants and particulate drug delivery systems (DDS) used in the treatment of ophthalmic diseases. The report focuses on current commercial implants and those currently in development, their respective applications and they potential mid-term and long-term evolution.

The overall market is likely to be more than USD 6.5 billion in the coming decade. The opportunity could be much higher in the outer years, especially driven by the regulatory approval of implants for delivery of biologics. Such drug delivery systems are expected to hold substantial potential as they result in improved retention time compared to topical applications and are more convenient than regular intravitreal injections, especially in the treatment of posterior eye diseases.

Topics CoveredInclude:

• Current and future technological progress
• Product pipeline
• Target (News - Alert) indications
• Industry and academic research programs
• New evolving opportunities
• Technical parameters (drug elution rate, amount of drug delivered, life of implant etc.)
• Likely user friendliness of various delivery systems

The base year for the report is 2014. The report provides market forecasts for the following two time horizons: 2015 - 2020 and 2020 - 2025. In addition to the above, we have also provided our own independent perspective on the key drivers behind the growth of this market, likely challenges and potential threats. The research, analysis and insights presented in this report include the sales potential of various marketed and late stage pipeline ocular sustained drug delivery systems based on the current expected launch timelines, adoption rates and the estimated end-use price points. The figures mentioned in this report are in USD, unless otherwise specified.

Companies Mentioned Include:

• Actavis Plc
• Aerie Pharmaceutical
• Ain Shams University, Cairo, Egypt
• Alcon
• Alimera Sciences
• Allergan
• Alliance Medical Products Inc
• Alpha Associates
• Auritec Pharmaceuticals
• Avida Group
• Bausch & Lomb
• Baxter Venture
• Bayer Healthcare
• BCN (News - Alert) Peptides
• Brown Advisory

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Product Profiles and Sales Forecast

6. Company Profiles

7. Venture Capital Support

8. Recent Partnerships

9. Swot Analysis

10. Interview Transcripts

11. Conclusion

12. Appendix 1: Tabulated Data

13. Appendix 2: List Of Companies

For more information visit http://www.researchandmarkets.com/research/sz483m/sustained_release

View source version on businesswire.com: http://www.businesswire.com/news/home/20151125005813/en/

[ Back To TMCnet.com's Homepage ]